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Purpose: To evaluate the effectiveness of laser photocoagulation as adjuvant therapy in the treatment of 
large macular holes.
Methods: A randomized clinical trial. Thirty-one eyes from 29 subjects with idiopathic macular holes of 
diameters larger than 400 µm were randomized into a laser group and a control group. All eyes underwent 
vitrectomy with peeling of the internal limiting membrane. Contrary to the control group eyes, the laser group 
eyes underwent laser photocoagulation at the center of the macular hole before vitrectomy. Visual acuity and 
anatomic outcomes assessed by optical coherence tomography (OCT) were analyzed 3 months after surgery.
Results: On postoperative OCT, closure of the macular hole was noted in 17 of the 18 (94.4%) laser group 
eyes and 10 of the 13 (76.9%) control group eyes. Hole closure without bare retinal pigment epithelium was 
observed in 16 eyes in the laser group and 6 eyes in the control group (P<0.05). The amount of improve-
ment in logMAR visual acuity 3 months after surgery was 0.40±0.29 in the laser group, and 0.19±0.23 in 
the control group (P<0.05).
Conclusions: Laser photocoagulation constitutes a potent adjuvant therapy that may improve anatomical and 
visual outcomes of surgery for macular holes larger than 400 µm.  Korean Journal of Ophthalmology 20(2): 
93-98, 2006
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The primary goal of surgery for macular holes is to induce 
visual improvement via the reappositioning of the detached 
or thickened rim of the neurosensory retina to the retinal 
pigment epithelium. The macular hole is sealed by formation 
of a glial plug, which reattaches the rim of the neurosensory 
retina around the edges of the hole.
1-3 In order to improve 
the success rate of surgery, it is necessary to provide stimulus 
to the glial cells, a template for migration, and a scaffold for 
proliferation.
4 Several adjuvants have been introduced in the 
hopes of improving the outcomes associated with macular 
hole surgery,
5-8 but the effects remain somewhat contro-
versial.
9-11 
Laser photocoagulation at the center of the macular hole, 
one of the adjuvant therapies for the treatment of macular 
holes, was introduced by Del Priore.
12 The theoretical basis 
of this procedure is that the retinal pigment epithelium will 
produce cytokines after completion of laser photocoagulation 
which will promote the formation of a glial plug to close the 
macular hole.
13-15 Several consecutive series have previously 
demonstrated that laser photocoagulation, when performed as 
an adjuvant therapy, is able to promote the closure of primary 
or recurrent macular holes and, as a result, improve visual 
outcomes.
13,14,16-18 The above results suggest that laser photo-
coagulation might constitute a useful adjuvant therapy for the 
treatment of idiopathic macular holes. However, this benefit 
has not been confirmed in a controlled clinical trial.
In this randomized clinical trial, we attempted to evaluate 
the effectiveness of laser photocoagulation as an adjuvant 
therapy in the surgical treatment of macular holes with 
diameters larger than 400 µm. 
Materials and Methods
1. Patient eligibility
This study was conducted between April 2004 and March 
2005. A total of 31 idiopathic macular holes in 29 patients 
were included in this trial. All patients were of Asian 
extraction. Five males and 24 females were included. Patients 
were included in this study if they exhibited a full-thickness 
macular hole with a diameter larger than 400 µm, as assessed 
by optical coherence tomography (OCT). Eyes with any other 
ocular diseases, including macular degeneration, diabetic 
retinopathy, history of glaucoma, or intraocular pressure Korean  J  Ophthalmol  Vol.20,  No.2,  2006
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higher than 30 mmHg at baseline, were excluded from this 
study. Eyes with previous history of intraocular surgery, with 
the exception of cataract extraction, were also determined to 
be ineligible. Highly myopic eyes (>5 diopters) with macular 
holes and eyes with traumatic macular holes were excluded 
from this trial. This study was approved by the institutional 
review board. All patients provided informed consent after 
study protocol and surgical risks were explained. 
2. Preoperative examination
For each studied eye, baseline data included the date of 
onset, objective refraction values, best-corrected visual acuity 
as measured by the Early Treatment Diabetic Retinopathy 
Study (ETDRS) charts,
19 slit-lamp examination, applanation 
tonometry, biomicroscopic fundus examination, fundus photo-
graphy, and optical coherence tomography (OCT3, Humphrey 
Instrument, San Leandro, Calif). Preoperative macular hole 
diameter was acquired by taking the average of the vertical 
and horizontal diameters, both of which were determined at 
the minimal extent of the hole on OCT examination. 
3. Study groups and randomization 
All eyes included in this trial were randomized into 2 
groups: the laser group and the control group. Allocation into 
each group was dependent on the last digit of the subject’s 
hospital identification number. Odd numbers were assigned to 
the laser group and even numbers to control group. The 
resultant randomization code was masked to all investigators 
or clinical observers, except the one who applied laser 
photocoagulation, until the completion of data collection. We 
determined there to be no differences between the two 
groups, except that laser photocoagulation at the center of 
macular hole was applied only to the eyes of the laser group. 
Best-corrected visual acuity with refraction on each visit and 
OCT were examined throughout the study period by masked 
independent observers.
Two patients exhibited bilateral macular holes. The eyes 
of each patient with bilateral macular holes were randomly 
allocated such that one eye had laser and other was a control 
eye. 
4. Laser photocoagulation at the center of the 
macular hole
In the laser group, laser photocoagulation was performed 
before the vitrectomy, but on the same day. The procedure 
was performed with the patient under topical anesthesia using 
a fundus contact lens (TransEquator
Ⓡ lens, Volk Optical Inc., 
Ohio), slit-lamp delivery system, and an argon green 
wavelength laser (Novus Omni
TM; Coherent Inc., Palo Alto, 
Calif). Three burns of 100-µm size, 0.04~0.1 second 
duration, and 60~100 mW were applied directly to the 
pigment epithelium at the center of the macular hole. The 
endpoint of laser photocoagulation resulted in the appearance 
of subtle gray burns with a triangular arrangement. 
5. Surgical procedures
Vitrectomies were performed by one surgeon (S.W.K), 
using the same surgical technique for all macular holes. The 
vitreous body and posterior hyaloid face were removed via 
standard three-port pars plana vitrectomy. When present, the 
epiretinal membrane around the hole was removed. The 
circular laminorrhexis of the retinal internal limiting mem-
brane was successfully performed in all eyes of both groups. 
After complete fluid-air exchange, the air in the vitreous 
cavity was then replaced with a 14% perfluoropropane gas 
mixture. 
Postoperative face-down positioning instructions were 
given, and the patients typically maintained this position for 
at least 2 weeks. 
6. Postoperative evaluation
At 1, 4, and 8 weeks after vitrectomy, patients were 
encouraged to recieve ocular examinations. At the 3-month 
follow-up visit, all patients received complete ophthalmo-
logical examinations, which included evaluation of best- 
corrected ETDRS visual acuity, biomicroscopic fundus 
examination, and OCT. Postoperative 3-month data were 
used for analysis. 
Assessment of anatomic results after surgery for macular 
hole depended on OCT images, rather than on biomicros-
copy, in order to reduce inter-observer bias. Accordingly, our 
masked investigators determined closure of the macular hole, 
as well as the types of closure achieved from the OCT image, 
Macular hole closure was defined on OCT as the flattening 
of the entire circumference of the macular hole against the 
retinal pigment epithelium. Eyes which were judged to have 
achieved the closure of the macular hole were then classified 
into two groups: type 1 closure and type 2 closure.
20 Type 
1 closure on OCT examination indicates that the macular 
hole has been closed without bare retinal pigment epithelium 
(Fig. 1A). Type 2 closure indicates the presence of bare 
retinal pigment epithelium on OCT examination, although the 
entire rim of the macular hole is attached to the underlying 
retinal pigment epithelium with a flattening of the cuff (Fig. 
1B). Reopening, in this study, was defined as the detection 
of an opened macular hole at any time after surgery for 
macular hole. Thus, primary failure and recurrent macular 
hole were lumped together under the term “reopening” for the 
purpose of analysis. 
7. Statistical analysis
ETDRS visual acuity values were converted to logarithms 
of the minimum angle of resolution (logMAR) values, for the 
purpose of statistical analysis. Since the numbers of patients HY  Cho,  et  al.  LASER  TREATMENT  IN  MACULAR  HOLE  SURGERY
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Fig. 1. Postoperative  funduscopic  findings  of  a  patient  with  bilateral  macular  holes.  The  preoperative  h o l e  d i a m e t e r  o f  t h e  r i g h t  a n d  left 
eyes was 689.5 µm and 711.5 µm, respectively. The left eye, which was randomized into the laser group, showed type 1 closure 3 months 
after  surgery  (A).  In  contrast,  the  right  eye  in  the  control  group  had  type  2  closure  (B).
Control  group Laser  group P-value
Number  of  eyes
Age  (year)
Sex  (M : F)
Duration  of  visual  impairment  (month)
Visual  acuity  (logMAR)
Diameter  of  macular  hole  (µm)
13
66.9±3.6
3:1 0
11.3±12.1
0.92±0.25
617.6±128.4
18
65.9±5.3
3:1 5
10.2±10.5
1.09±0.29
615.6±147.6
0.26*
0.68
†
0.88*
0.13*
0.54*
*Mann-Whitney  test, 
†Fisher’s  exact  test.
Table 1. Summary  of  preoperative  status  of  study  groups
in each group was small and the data were not normally 
distributed, a Mann-Whitney test was utilized to compare 
best-corrected visual acuity between the 2 groups. Compari-
sons of postoperative anatomic results and complications 
between the 2 groups were conducted via Fisher’s exact tests. 
Statistical analysis was conducted using SPSS software 
(version 12.0).
Results
The mean age of the patients was 66.4 years (range 55 to 
76 years). The laser group included 18 eyes and the control 
group consisted of 13 eyes. Tables 1 and 2 summarize the 
preoperative status and demographic characteristics of the 
patients in each group. All of the patients enrolled in this trial 
completed examinations 3 months after initial surgeries.
1. Anatomical outcome
Table 3 summarizes anatomical outcomes after macular 
hole surgery. When assessed by OCT, the macular hole 
closure was achieved in 17 of the 18 eyes (94.4%) in the 
laser group and in 10 of the 13 eyes (76.9%) in the control 
group (P=0.28). Type 1 closure on OCT examination was 
observed in 16 eyes (88.8%) in the laser group and 6 eyes 
(46.2%) in the control group. The rates of type 1 closure was 
significantly higher in the laser group, with an odds ratio of 
9.33 (P=0.02). Macular holes reopened in 3 of the control 
group eyes and in 1 laser group eye. All cases of reopening 
were managed by laser photocoagulation at the center of the 
macular hole, and fluid gas exchange with perfluoropropane 
gas. All 3 reopened control group macular holes closed after 
the additional intervention. The one reopened macular hole 
in the laser group, whose initial diameter was 961 µm, 
retained the reopened macular hole despite the additional 
procedure. 
Two patients exhibited bilateral macular holes. Type 1 
closure was achieved postoperatively in both of the laser Korean  J  Ophthalmol  Vol.20,  No.2,  2006
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Closed
Reopened Total
Type  1  closure Type  2  closure
Control  group
Laser  group
6
16
4
1
3
1
13
18
Type  1  closure  versus  type  2  closure  and  reopened;  Odds  ratio:  9.33,  P=0.02  (examined  with  Fisher’s  exact  test).
Table 3. Anatomical  results  of  macular  hole  surgery 
Control  group Laser  group
Less  than  6  months
6-12  months
More  than  12  months
6
5
2
6
9
3
Chi-square  test,  P>0.05. 
Table 2. Duration  of  subjective  visual  impairment  in 
study  groups
Fig. 2. Scatterplot distribution of preoperative versus postoperative 
Snellen visual acuity of all study eyes. The diagonal line represents 
no  change  in  visual  acuity.
group eyes, whereas the fellow eyes in the control group 
consistently exhibited type 2 closure (Fig. 1).
2. Visual outcome
Preoperative logMAR visual acuity was 1.09±0.29 (mean 
± standard deviation) in the laser group, and 0.92±0.25 in 
the control group (P=0.13). Postoperative logMAR visual 
acuity was 0.69±0.23 in the laser group and 0.73±0.23 in 
the control group (P=0.51). Preoperative visual acuity was 
poorer in the laser group rather than in the control group and 
so we compared the extent of visual improvement between 
the 2 groups. Changes in visual acuity in all of the individual 
cases enrolled in this study are shown in Figure 2. The 
amount of improvement in logMAR visual acuity 3 months 
after surgery was 0.40±0.29 in the laser group, which was 
significantly larger than that in the control group, 0.19±0.23 
(P=0.03). The amount of improvement in logMAR visual 
acuity among the eyes which achieved macular hole closure 
was 0.52±0.32 in the laser group and 0.31±0.30 in the 
control group (P=0.09). 
3. Complications
None of the patients experienced any intraoperative com-
plication. Four eyes in each group underwent cataract surgery 
during or after macular hole surgery. Postoperative elevation 
in intraocular pressure to more than 30 mmHg was noted in 
one eye, and was controlled with medical therapy.
Discussion
This study excluded macular holes with diameters of less 
than 400 µm, as most of these exhibited the complete sealing 
of macular hole postoperatively, without the necessity for any 
adjuvant therapy.
20-23 
Most of all, this study demonstrated that laser photo-
coagulation promotes the completeness of macular hole 
closure, and induces a greater degree of postoperative visual 
improvement at 3 months. Because it was identified that type 
1 closure was associated with larger postoperative visual 
improvement and less recurrence,
20 type 1 closure should be 
considered as an anatomic endpoint for better prognosis. 
Hence, it is both encouraging and clinically significant, that 
laser photocoagulation, when used as an adjuvant therapy, 
promoted the rate of the type 1 closure. 
One may raise the question whether type 2 closure in this 
study could be regarded as a form of closed macular hole. 
According to one review article,
24 the traditional biomicro-
scopic criterion of macular hole closure has been the 
flattened edge of the macular hole, which corresponds to type 
2 closure in this study. Compared with preoperative macular 
hole diameter, the diameter of foveal tissue defects in type 
2 closure was always smaller on OCT examination. Type 2 
closure also accompanied improved postoperative vision. 
Accordingly, type 2 closure should also be regarded as a type 
of anatomic success as in previous reports. 
The anatomic success rate (76.9%) in the control group 
seems lower than in recent studies employing similar surgical HY  Cho,  et  al.  LASER  TREATMENT  IN  MACULAR  HOLE  SURGERY
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techniques. We postulate that this difference might arise 
partly from the chronicity of the macular holes in our study. 
The mean durations of symptoms in both groups of our study 
was more than 10 months and the mean hole diameters were 
accordingly larger than 615 µm in both groups. Additionally, 
most of the previous reports did not determine the closure of 
macular holes by OCT but rather by biomicroscopy, which 
might also result in a different estimation of anatomic success 
from our study.
Some of the results in this study were noteworthy. First, 
after applying laser photocoagulation and fluid-gas exchange 
in cases of reopened macular holes, we achieved the closure 
of reopened macular holes in all 3 eyes which were initially 
included in the control group. Second, the laser-applied eyes 
of 2 patients with bilateral macular holes achieved the type 
1 closure, but the fellow eyes included in the control group 
consistently did not. These two results imply that laser 
photocoagulation at the center of the macular hole is a potent 
tool for the improvement of anatomic success.
The preoperative diameter of the one reopened macular 
hole in the laser group was 961 µm, the largest observed in 
this study. This suggests that laser photocoagulation at the 
center of the hole may promote macular hole closure, and 
type 1 closure in particular, but has limitations in cases of 
extremely large macular holes.
There would be concerns regarding central scotoma 
induced by laser photocoagulation. According to previous 
studies on the changes in visual fields, which utilized 
scanning laser ophthalmoscopic microperimetry after the laser 
photocoagulation for recurrent macular holes, only clinically 
insignificant changes in visual field could be observed.
16 The 
findings among the eyes which achieved anatomical success 
in our study indicated that the laser group eyes tended to 
show greater visual improvement than the control group eyes 
did (P=0.09). Therefore, laser photocoagulation at the center 
of the macular hole likely caused no serious problems in 
visual function, although we could not completely dismiss the 
possibility of a scotoma related to laser photocoagulation. 
Some modifications from previous studies were made with 
regard to the application of laser photocoagulation in this 
study. Laser photocoagulation was performed with a slit lamp 
delivery system instead of an endolaser, which allowed us to 
focus the laser spot on a more exact location and to titrate 
laser power more predictably. In addition, we applied three 
spots of 100 µm- sized laser burn, rather than one larger laser 
spot, which helped us to prevent excessive retinal pigment 
epithelial damage at the center of the large laser spot.
Compared with other modes of adjuvant therapy, laser 
photocoagulation at the center of the macular hole has several 
advantages. First, the technique is not associated with any 
additional complications such as intraocular inflammation, 
which may result from the intraocular application of trans-
forming growth factor-beta 2, autologous platelet concentrate, 
and tissue sealant.
5-8 Secondly, this technique is quite easy to 
apply, as it only requires a fundus laser photocoagulator. 
Third, the visual and anatomic benefits associated with the 
technique have been consistently suggested by a host of 
authors.
12-14
In conclusion, the results of this randomized trial suggest 
that laser photocoagulation at the center of macular holes 
causes no harm and may improve the anatomic and visual 
outcomes of surgery for idiopathic macular holes with 
diameters larger than 400 µm. Further studies with larger 
numbers of cases and longer-term follow-up are warranted.
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